View Past PerformanceOrphazyme バランスシートの健全性財務の健全性 基準チェック /66Orphazymeの総株主資本はDKK28.9M 、総負債はDKK0.0で、負債比率は0%となります。総資産と総負債はそれぞれDKK36.2MとDKK7.3Mです。主要情報0%負債資本比率DKK 0負債インタレスト・カバレッジ・レシオn/a現金DKK 30.34mエクイティDKK 28.88m負債合計DKK 7.30m総資産DKK 36.18m財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Nov 25Strategic Partners A/S, Annual General Meeting, Apr 28, 2026Strategic Partners A/S, Annual General Meeting, Apr 28, 2026, at 10:00 Romance Standard Time.お知らせ • Sep 17Strategic Partners A/S Revises Earnings Guidance for the Fiscal Year 2025Strategic Partners A/S revised earnings guidance for the fiscal year 2025. Based on the first half of the year the company changes its outlook from previously an operating loss in the range of DKK -3 to -4 million to DKK -2 to -3 million.お知らせ • Jan 10Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP).Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. As part of acquisition, 2,327,058 shares were acquired. Stockslatten AB completed the acquisition of 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025.お知らせ • Dec 27Strategic Partners A/S, Annual General Meeting, Mar 26, 2025Strategic Partners A/S, Annual General Meeting, Mar 26, 2025.お知らせ • Feb 22Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024. Orphazyme informed CombiGene that they in total have acquired approximately 10% of the outstanding shares in CombiGene, which makes Orphazyme one of the larger shareholders in the Company. Orphazyme A/S (CPSE:ORPHA) completed the acquisition of an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024.New Risk • Jun 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.25m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.118m free cash flow). Shares are highly illiquid. Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$9.25m market cap).お知らせ • May 31+ 2 more updatesOrphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFOOrphazyme A/S announced that the board of directors and CFO Anders Fink Vadsholt has entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023.お知らせ • May 18Orphazyme A/S Announces Board ChangesOrphazyme A/S announced that during the Annual General Meeting on May 17, 2023, Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacy as members of the Board of Directors. Michael Schlomo Gabriely Hove, Jakob Færch Bendtsen and Jakob Alsted Have were elected as new members of the Board of Directors by the general meeting.お知らせ • Dec 06Orphazyme A/S to Report First Half, 2023 Results on Sep 12, 2023Orphazyme A/S announced that they will report first half, 2023 results on Sep 12, 2023財務状況分析短期負債: OZYM.Fの 短期資産 ( DKK36.2M ) が 短期負債 ( DKK7.3M ) を超えています。長期負債: OZYM.Fには長期負債はありません。デット・ツー・エクイティの歴史と分析負債レベル: OZYM.Fは負債がありません。負債の削減: OZYM.F 5 年前には負債がありませんでした。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: OZYM.Fは、現在の フリーキャッシュフロー に基づき、1 年以上にわたって十分な キャッシュランウェイ を有しています。キャッシュランウェイの予測: OZYM.Fは、フリー キャッシュ フローが毎年13 % の歴史的率で減少し続ける場合、 1.6年間十分なキャッシュ ランウェイを有しています。健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/03/03 03:12終値2023/12/05 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Strategic Partners A/S これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Tazeen AhmadBofA Global ResearchJacob LademannCarnegie Investment Bank ABThomas BowersDanske Bank4 その他のアナリストを表示
お知らせ • Nov 25Strategic Partners A/S, Annual General Meeting, Apr 28, 2026Strategic Partners A/S, Annual General Meeting, Apr 28, 2026, at 10:00 Romance Standard Time.
お知らせ • Sep 17Strategic Partners A/S Revises Earnings Guidance for the Fiscal Year 2025Strategic Partners A/S revised earnings guidance for the fiscal year 2025. Based on the first half of the year the company changes its outlook from previously an operating loss in the range of DKK -3 to -4 million to DKK -2 to -3 million.
お知らせ • Jan 10Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP).Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. As part of acquisition, 2,327,058 shares were acquired. Stockslatten AB completed the acquisition of 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025.
お知らせ • Dec 27Strategic Partners A/S, Annual General Meeting, Mar 26, 2025Strategic Partners A/S, Annual General Meeting, Mar 26, 2025.
お知らせ • Feb 22Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024. Orphazyme informed CombiGene that they in total have acquired approximately 10% of the outstanding shares in CombiGene, which makes Orphazyme one of the larger shareholders in the Company. Orphazyme A/S (CPSE:ORPHA) completed the acquisition of an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024.
New Risk • Jun 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.25m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.118m free cash flow). Shares are highly illiquid. Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$9.25m market cap).
お知らせ • May 31+ 2 more updatesOrphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFOOrphazyme A/S announced that the board of directors and CFO Anders Fink Vadsholt has entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023.
お知らせ • May 18Orphazyme A/S Announces Board ChangesOrphazyme A/S announced that during the Annual General Meeting on May 17, 2023, Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacy as members of the Board of Directors. Michael Schlomo Gabriely Hove, Jakob Færch Bendtsen and Jakob Alsted Have were elected as new members of the Board of Directors by the general meeting.
お知らせ • Dec 06Orphazyme A/S to Report First Half, 2023 Results on Sep 12, 2023Orphazyme A/S announced that they will report first half, 2023 results on Sep 12, 2023